Adaptive Vaccination Solutions for Specialized Environments

Publication ID: 24-11857615_0004_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Adaptive Vaccination Solutions for Specialized Environments,” Published Technical Disclosure No. 24-11857615_0004_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857615_0004_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,615.

Summary of the Inventive Concept

This inventive concept adapts the original peptides derived from Acinetobacter baumannii for vaccination in specialized environments, such as high-security facilities, disaster relief areas, extreme weather conditions, high-altitude environments, and high-stress environments.

Background and Problem Solved

The original patent relates to novel proteins and polynucleotides derived from Acinetobacter baumannii for antimicrobial prophylaxis and therapy. However, these compositions may not be suitable for specific, narrow markets or unique operational environments. The present inventive concept addresses this limitation by adapting the peptides for use in specialized environments, providing targeted solutions for these niche markets.

Detailed Description of the Inventive Concept

The new inventive concept comprises a system, method, or portable kit for vaccination in specialized environments, utilizing peptides derived from Acinetobacter baumannii with a sequence identity of at least 90% to SEQ ID NO: 27. These solutions are adapted for use in high-security facilities, disaster relief areas, extreme weather conditions, high-altitude environments, and high-stress environments, ensuring effective vaccination in these unique contexts.

Novelty and Inventive Step

The new claims introduce novel and non-obvious adaptations of the original peptides for vaccination in specialized environments, which are not anticipated by the original patent. The inventive step lies in the specific combinations of peptides, adjuvants, and carriers tailored to these niche markets, providing a unique value proposition for users in these environments.

Alternative Embodiments and Variations

Alternative embodiments may include varying the sequence identity of the peptides, using different adjuvants or carriers, or incorporating additional components to enhance the vaccination process. Variations may also include adapting the solutions for use in other specialized environments, such as space exploration or remote communities.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, targeting niche markets such as high-security facilities, disaster relief organizations, and extreme weather condition responders. The solutions may also be applicable to other industries, such as aerospace or remote community healthcare, providing a broad market opportunity.

CPC Classifications

SectionClassGroup
A A61 A61K39/104
C C07 C07K14/212
A A61 A61K2039/543
A A61 A61K2039/55505
A A61 A61K2039/55566
G G01 G01N2333/22
G G01 G01N2469/20

Original Patent Information

Patent NumberUS 11,857,615
TitlePeptides derived from Acinetobacter baumannii and their use in vaccination
Assignee(s)Evaxion Biotech A/S